Serina Therapeutics
About: Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Employees: 13
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
19% more capital invested
Capital invested by funds: $1.6M [Q4 2024] → $1.9M (+$305K) [Q1 2025]
0% more funds holding
Funds holding: 25 [Q4 2024] → 25 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.21% less ownership
Funds ownership: 3.59% [Q4 2024] → 3.38% (-0.21%) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SER.
Financial journalist opinion
Based on 5 articles about SER published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina's common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).
Neutral
GlobeNewsWire
1 week ago
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”).
Neutral
GlobeNewsWire
2 weeks ago
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson's Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.
Neutral
GlobeNewsWire
3 weeks ago
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.
Neutral
GlobeNewsWire
3 weeks ago
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on securing $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.
Neutral
GlobeNewsWire
1 month ago
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"
Featuring Serina Therapeutics' CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise values Recognize the patterns that can lead to strong investment returns Meet with Serina 's CEO Steven A. Ledger Register at Smartest-Bet.TribePublic.com HUNTSVILLE, AL, June 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina's CEO, Steven A.
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics –
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an “Option Grant”). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were approved by the Compensation Committee of Serina's Board of Directors on March 20, 2025, pursuant to Serina's 2024 Inducement Equity Plan to align their interests with Serina's stockholders and to promote the success of Serina's business. The Option Grants were made in reliance on the employment inducement exemption under the NYSE American's Company Guide Section 711(a) which requires public disclosure of inducement awards. Serina is issuing this press release pursuant to Section 711(a) of NYSE American's Company Guide. The Option Grants shall vest and become exercisable with respect to one-fourth of the aggregate number of shares subject to each Option Grant on the first anniversary of the grant date, and the remaining three-fourths of the aggregate number of shares subject to each Option Grant shall vest in a series of three substantially equal annual installments thereafter, such that the Option Grant will be vested as of the third anniversary of the grant date, subject to continued employment with Serina.
Neutral
GlobeNewsWire
2 months ago
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights.
Neutral
GlobeNewsWire
2 months ago
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.
Charts implemented using Lightweight Charts™